Cargando…

Perspectives on neuroreparative therapies for treating multiple sclerosis

Detalles Bibliográficos
Autor principal:	Xiao, Junhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2015
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705784/ https://www.ncbi.nlm.nih.gov/pubmed/26807107 http://dx.doi.org/10.4103/1673-5374.169610

Ejemplares similares

Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis
por: Medina-Rodríguez, Eva María, et al.
Publicado: (2017)

An innovative small molecule for promoting neuroreparative strategies
por: Colabufo, Nicola Antonio, et al.
Publicado: (2018)

Editorial: Neurodegeneration, cell signaling and neuroreparative strategies
por: Vaz, Ana Rita, et al.
Publicado: (2022)

Glutamate Scavenging as a Neuroreparative Strategy in Ischemic Stroke
por: Kaplan-Arabaci, Oykum, et al.
Publicado: (2022)

Editorial: Neurodegeneration, cell signaling and neuroreparative strategies, Volume II
por: Vaz, Ana Rita, et al.
Publicado: (2023)

Targeting metabolism to treat multiple sclerosis
por: Bhargava, Pavan
Publicado: (2020)

Tremor in Multiple Sclerosis—An Overview and Future Perspectives
por: Makhoul, Karim, et al.
Publicado: (2020)

COVID-19 and neurological sequelae: Vitamin D as a possible neuroprotective and/or neuroreparative agent
por: Menéndez, Sebastián García, et al.
Publicado: (2022)

Potential Risks and Benefits of Multiple Sclerosis Immune Therapies in the COVID-19 Era: Clinical and Immunological Perspectives
por: Bhise, Vikram, et al.
Publicado: (2021)

Drug repurposing for neuroregeneration in multiple sclerosis
por: Küry, Patrick, et al.
Publicado: (2018)

Multiple sclerosis drug repurposing for neuroregeneration
por: Göttle, Peter, et al.
Publicado: (2023)

Soluble interleukin 23 receptor gene therapy with adeno-associated vectors for the treatment of multiple sclerosis
por: Edo, Ángel, et al.
Publicado: (2017)

Multiple Sclerosis: Overview of Disease-Modifying Agents
por: Finkelsztejn, Alessandro
Publicado: (2014)

Immunological role of sulfatide in the pathogenesis of multiple sclerosis
por: Hamatani, Mio, et al.
Publicado: (2023)

Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies
por: D'Amico, Emanuele, et al.
Publicado: (2021)

Ependymal cells and multiple sclerosis: proposing a relationship
por: Hatrock, Dale, et al.
Publicado: (2019)

Orexin/hypocretinin in multiple sclerosis and experimental autoimmune encephalomyelitis
por: Pallais, Jean Pierre, et al.
Publicado: (2019)

Ethical use of off-label disease-modifying therapies for multiple sclerosis
por: Laurson-Doube, Joanna, et al.
Publicado: (2021)

Focusing on caveolin-1 in CNS autoimmune disease: multiple sclerosis
por: Wu, Hao, et al.
Publicado: (2016)

Galectin-3 prospects as a therapeutic agent for multiple sclerosis
por: Thomas, Laura, et al.
Publicado: (2019)

Myelin positron emission tomography (PET) imaging in multiple sclerosis
por: de Paula Faria, Daniele
Publicado: (2020)

The Importance of the Cognitive Aspects of Vocational Rehabilitation for Individuals With Multiple Sclerosis
por: Kennedy, Winston, et al.
Publicado: (2020)

Brain network correlates of epilepsy occurrence in multiple sclerosis and neuroinflammation
por: Ciolac, Dumitru, et al.
Publicado: (2022)

Trans-synaptic degeneration as a mechanism of neurodegeneration in multiple sclerosis
por: Murphy, Olwen C., et al.
Publicado: (2023)

Patient and Physician Perspectives on Systemic Sclerosis–Associated Interstitial Lung Disease
por: Cheema, Tariq J, et al.
Publicado: (2020)

Reciprocal Regulation of Substance P and IL-12/IL-23 and the Associated Cytokines, IFNγ/IL-17: A Perspective on the Relevance of This Interaction to Multiple Sclerosis
por: Vilisaar, Janek, et al.
Publicado: (2015)

Amyotrophic lateral sclerosis disease modifying therapeutics: a cell biological perspective
por: Tang, Bor Luen
Publicado: (2017)

Environmental enrichment as a promising strategy for aiding multiple sclerosis treatment
por: Silva, Berenice Anabel, et al.
Publicado: (2020)

Role of CD20(+) T cells in multiple sclerosis: implications for treatment with ocrelizumab
por: Gingele, Stefan, et al.
Publicado: (2019)

A Perspective on Imiquimod Microneedles for Treating Warts
por: Chiu, Tsu-Man, et al.
Publicado: (2021)

Biochemical indicators for neuronal regeneration during intrathecal triamcinolone application in multiple sclerosis
por: Müller, Thomas, et al.
Publicado: (2015)

Pharmacological interventions targeting nuclear factor-kappa B signaling in multiple sclerosis
por: De Kleijn, Kim M. A., et al.
Publicado: (2021)

Multiple sclerosis: why we should focus on both sides of the (auto) antibody
por: den Dunnen, Jeroen, et al.
Publicado: (2021)

Neuronal and endothelial transglutaminase-2 expression in experimental autoimmune encephalomyelitis and multiple sclerosis
por: Pearse, Damien D., et al.
Publicado: (2021)

Synaptic pathology in multiple sclerosis: a role for Nogo-A signaling in astrocytes?
por: Espírito-Santo, Sheila, et al.
Publicado: (2022)

Emerging role of neuregulin-1beta1 in pathogenesis and progression of multiple sclerosis
por: Ziaee, Seyyed Mohyeddin, et al.
Publicado: (2022)

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
por: Davies, Faith E., et al.
Publicado: (2022)

Neuronal gene transcription modulates demyelination and remyelination in a mouse model of multiple sclerosis
por: Anastasiadou, Sofia, et al.
Publicado: (2015)

Chemotactic signaling and beyond: link between interleukin-16 and axonal degeneration in multiple sclerosis
por: Skundric, Dusanka S.
Publicado: (2015)

Can Blood Gene Expression Predict Which Patients with Multiple Sclerosis Will Respond to Interferon?
por: Kaminski, Naftali, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_t2g754vjla498hcl5d3hptijtd